Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REAL-WORLD CLINICAL PATTERNS OF CARE AND OUTCOMES AMONG PATIENTS IN AFRICA MIDDLE EAST (AFME) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING SUNITINIB AS FIRST LINE THERAPY (OPTIMISE).

NCT03140176 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03140176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03140176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REAL-WORLD CLINICAL PATTERNS OF CARE AND OUTCOMES AMONG PATIENTS IN AFRICA MIDDLE EAST (AFME) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING SUNITINIB AS FIRST LINE THERAPY (OPTIMISE).
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
August 15, 2017
Completion date
January 22, 2022
Enrollment
77 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma